

Alzheimer's Disease: The Role of Hyphenated Analytical Systems in the Analysis of Therapeutic Agents Effective against the Disease in Biological Fluids

Mbah Chika John*

Faculty of Pharmaceutical Sciences, University of Nigeria, Nigeria

***Corresponding author:** Mbah Chika John, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria, Email: chika.mbah@unn.edu.ng

Editorial

Volume 3 Issue 4

Received Date: November 26, 2018

Published Date: December 06, 2018

DOI: 10.23880/apct-16000144

Editorial

Alzheimer's disease (AD) is a neurodegenerative disorder (brain disorder) that is irreversible, progressive and gradually destroys memory, thinking skills and ultimately the ability to carry out the minimal activities [1]. It is the most frequent type of dementia among elderly people. Dementia is characterized by the loss of cognitive functioning such as thinking, remembering, reasoning and behavioral abilities. Neuronal degeneration in Alzheimer's disease could be as a result of deposition of β -amyloid protein ($A\beta$) in the form of senile plaques, intraneuronal neurofibrillary tangles, protein tau(τ) hyperphosphorylation, oxidative stress and inflammation [2]. The neurochemical changes in Alzheimer's disease form the basis for the symptomatic treatment with drugs like donepezil, galantamine, memantine, rivastigmine and tacrine. They are used orally in the treatment of mild to moderate Alzheimer's disease. These drugs are competitive and reversible cholinesterase inhibitors (AChEI) inhibiting the activity of enzyme cholinesterase and increasing the level of acetylcholine in brain. A dysfunction of glutamatergic neurotransmission is also considered to be involved in the etiology of the disease. Memantine, an N-methyl D-aspartate antagonist (NMDA) acts on the glutamatergic system by blocking NMDA glutamate receptors and is utilized to treat moderate to severe form of the disease. Similarly, donepezil is the most widely used cholinesterase inhibitor probably due to its 100% bioavailability and ability to cross the blood-brain barrier.

A hyphenated technique is an on-line combination of a separation technique and one or more spectroscopic

detection techniques [3]. It entails linking liquid chromatography (LC), usually a high-performance liquid chromatography (HPLC), gas chromatography (GC), or capillary electrophoresis (CE) to spectroscopic detection techniques such as photodiode array (PDA) UV-Vis absorbance, Fourier-transform infrared (FTIR), nuclear magnetic resonance (NMR), mass spectroscopy (MS). Due to the chronic nature and debilitating features of the disease, it has become very important to have a specific method for measuring these drugs in various biological matrices such as blood, serum, urine and cerebrospinal fluid etc. Determining them in long-term treatment enables drug doses to be adjusted, therapeutic effects to be ascertained and patient compliance to be ensured. Several methods reported for the determination of the clinically used cholinesterase inhibitors in biological matrices are mostly hyphenated analytical systems. Non-hyphenated analytical methods are not frequently used because plasma volume requirement is high, sensitivity might be inadequate for pharmacokinetic studies, multiple sample preparation and extraction procedures are time-consuming.

Detection methods such as ultraviolet (UV), fluorescence have been used for donepezil, rivastigmine, galantamine, tacrine except memantine that lacks chromophore. However, derivatization procedures allow memantine to be detected by these detection methods. Mass spectrometry detection method has also been used for all cholinesterase inhibitors. Although, several methods have been reported for the assay of each of the cholinesterase inhibitors in biological fluids, only two to

three analytical methods shall be highlighted. Literature search has revealed that donepezil has been determined in human plasma by liquid chromatography/tandem mass spectrometry [4], high performance liquid chromatography with fluorescence detection [5]. Capillary zone electrophoretic technique [6] and high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) [7] have been employed to determine galanthamine in biological fluids. The determination of rivastigmine, a relatively new drug used for the treatment of Alzheimer's disease has been done using fluorimetric method [8], HPLC [9], liquid chromatography-tandem mass spectrometry (LC-MS-MS) [10]. Furthermore, memantine has been determined by HPLC-MS-MS [11] and HPLC-MS [12] while tacrine has been determined by HPLC methods [13,14].

In conclusion, only few non-hyphenated analytical techniques have been used to determine clinically cholinesterase inhibitors for Alzheimer's disease. Amongst the hyphenated analytical methods, HPLC-MS/MS method has proven to be the analytical method of choice for the quantification of Alzheimer's disease drugs in both preclinical and clinical studies. This might be as a result of its specificity, accuracy, reproducibility, shortened analysis time, higher sample throughput, selectivity, high sensitivity and lower cost of analysis. Finally, hyphenated methods (in particular HPLC-MS/MS) have successfully been used to analyze therapeutic agents for Alzheimer's disease in human biological fluid samples for application in pharmacokinetic, bioavailability, or bioequivalence studies.

References

1. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, et al. (2007) Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. *Eur J Neurol* 14: 1-26.
2. Wang JM, Sun C (2010) Calcium and neurogenesis in Alzheimer's disease. *Front Neurosci* 4: 194-199.
3. Rouessac F, Rouessac A (2004) *Chemical Analysis: Modern Instrumentation methods and Techniques*, English (Edn.), John Wiley & Sons Ltd, New Jersey, pp: 8.
4. Xie Z, Liao Q, Xu X, Yao M, Wan J, et al. (2006) Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. *Rapid Commun Mass Spectrom* 20(21): 3193-3198.
5. Abonassif AM, Hefnawy MM, Kassem MG, Mostafa GAE (2011) Determination of donepezil hydrochloride in human plasma and pharmaceutical formulations by HPLC with fluorescence detection. *Acta Pharm* 61(4): 403-413.
6. Pokorna L, Revilla A, Havela J, Patocka J (1999) Capillary zone electrophoresis determination of galanthamine in biological fluids and pharmaceutical preparatives: Experimental design and artificial neural network optimization. *Electrophoresis* 20(10): 1993-1997.
7. Sulochanaa SP, Sharmab K, Mullangib R, Sukumarana SK (2014) Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease. *Biomed Chromatogr* 28(11): 1431-1490.
8. Karthik A, Subramanian GS, Surulivelrajan M, Ranjithkumar A, Kamat SB (2008) Fluorimetric determination of rivastigmine in rat plasma by a reverse phase high performance liquid chromatographic method. Application to a pharmacokinetic study. *Arzneimittel forschung* 58(5): 205-210.
9. Amini H, Ahmadiani A (2010) High performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. *J Pharm Res* 9(2): 115-121.
10. Bhatt J, Subbaiah G, Kambli S, Shah B, Nigam S, et al. (2007) A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* 852(1-2): 115-121.
11. Liu MY, Meng SN, Wu HZ, Wang S, Wei MJ (2008) Pharmacokinetics of single-dose memantine in healthy Chinese volunteers using an analytic method of liquid chromatography tandem mass spectrometry. *Clin Ther* 30(4): 641-653.
12. Liu W, Bi K, Liu X, Zhao J, Chen X (2009) Cloud-point extraction combined with LC-MS for analysis of memantine in rat plasma. *Chromatographia* 69: 837-842.

Advances in Pharmacology and Clinical Trials

13. Hsu RS, Dileo EM, Chesson SM (1990) High performance liquid chromatography for the determination of tacrine and its metabolites in plasma. *J Chromatogr* 530(1): 170-176.
14. Hansen LL, Larsen JT, Broesen K (1998) Determination of tacrine and its metabolites in human plasma and urine by high performance liquid chromatography and fluorescence detection. *J Chromatogr B Biomed Sci Appl* 712(1-2): 183-191.

